TY - JOUR
T1 - Interactions of single-wall carbon nanotubes with endothelial cells
AU - Albini, Adriana
AU - Mussi, Valentina
AU - Parodi, Alessandro
AU - Ventura, Agostina
AU - Principi, Elisa
AU - Tegami, Sara
AU - Rocchia, Massimiliano
AU - Francheschi, Enrico
AU - Sogno, Ilaria
AU - Cammarota, Rosaria
AU - Finzi, Giovanna
AU - Sessa, Fausto
AU - Noonan, Douglas McClain
AU - Valbusa, Ugo
N1 - Funding Information:
This study was supported by a grant from the Comitato Interministeriale per la Programmazione Economica (CIPE) and by funds from the Compagnia di San Paolo to CBA and the AIRC (Associazione Italiana per la Ricerca sul Cancro) to Multimedica Onlus.
Funding Information:
A.V. was in the Vaccine Prevention PhD program of the University of Genoa and is the recipient of a FIRC fellowship. I.S. is in the Molecular and Cellular Biology PhD program of the University of Insubria, and R.C. is a PhD student at the Department of Molecular Medicine, University of Milan, Via Fratelli Cervi, Segrate.
PY - 2010/4
Y1 - 2010/4
N2 - Single-wall carbon nanotubes (SWCNTs) could be promising delivery vehicles for cancer therapy. These carriers are generally introduced intravenously, however, little is known of their interactions with endothelial cells, the cells lining vessels and mediating clearance of nanoparticles. Here we show that SWCNTs of 1 to 5 μm in length, both "pristine" and functionalized by oxidation, had limited toxicity for endothelial cells in vitro as determined by growth, migration morphogenesis, and survival assays. Endothelial cells transiently took up SWCNTs, and several lines of data indicated that they were associated with an enhanced acidic vesicle compartment within the endothelial cells. Our findings of SWCNT interactions with endothelial cells suggest these may be optimal vehicles for targeting the vasculature and potential carriers of anti-angiogenic drugs. The implications on their biological activity must be taken into account when considering the use of these nanoparticles for therapeutic delivery of drugs. From the Clinical Editor: Interactions of single walled carbon nanotubes (SWCNTs) with endothelial cells following IV administration remains unclear. Functionalized and naïve SWCNTs of 1-5 mm in length had limited toxicity to endothelial cells in vitro. Endothelial cells transiently took up SWCNTs and were associated with an enhanced acidic vesicle compartment within the cells. These findings suggest that SWCNTs may be promising vehicles for targeting the vasculature and potential carriers of anti-angiogenic drugs.
AB - Single-wall carbon nanotubes (SWCNTs) could be promising delivery vehicles for cancer therapy. These carriers are generally introduced intravenously, however, little is known of their interactions with endothelial cells, the cells lining vessels and mediating clearance of nanoparticles. Here we show that SWCNTs of 1 to 5 μm in length, both "pristine" and functionalized by oxidation, had limited toxicity for endothelial cells in vitro as determined by growth, migration morphogenesis, and survival assays. Endothelial cells transiently took up SWCNTs, and several lines of data indicated that they were associated with an enhanced acidic vesicle compartment within the endothelial cells. Our findings of SWCNT interactions with endothelial cells suggest these may be optimal vehicles for targeting the vasculature and potential carriers of anti-angiogenic drugs. The implications on their biological activity must be taken into account when considering the use of these nanoparticles for therapeutic delivery of drugs. From the Clinical Editor: Interactions of single walled carbon nanotubes (SWCNTs) with endothelial cells following IV administration remains unclear. Functionalized and naïve SWCNTs of 1-5 mm in length had limited toxicity to endothelial cells in vitro. Endothelial cells transiently took up SWCNTs and were associated with an enhanced acidic vesicle compartment within the cells. These findings suggest that SWCNTs may be promising vehicles for targeting the vasculature and potential carriers of anti-angiogenic drugs.
KW - Angiogenesis
KW - Endothelium
KW - Nanoparticles
KW - Nanotubes
UR - http://www.scopus.com/inward/record.url?scp=77950299063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950299063&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2009.08.001
DO - 10.1016/j.nano.2009.08.001
M3 - Article
C2 - 19699323
AN - SCOPUS:77950299063
VL - 6
SP - 277
EP - 288
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
SN - 1549-9634
IS - 2
ER -